Scroll
down

Publications of 2024

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.

Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group.

Lancet. | 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. PMID: 39096929 Clinical Trial.

Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study.

Rocca J, Beydon M, Le Guern V, Hachulla E, Couderc M, Jousse-Joulin S, Devauchelle-Pensec V, Gottenberg JE, Vittecoq O, Lavigne C, Schmidt J, Larroche C, Mariette X, Seror R, Nocturne G.

Lancet Rheumatol. | 2024 Aug 22:S2665-9913(24)00198-X. doi: 10.1016/S2665-9913(24)00198-X. Online ahead of print. PMID: 39182508

Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome.

Plaçais M, Laparra A, Maria ATJ, Kramkimel N, Perret A, Manson G, Comont T, Coutte L, Nardin C, Ouali K, Danlos FX, Noël N, Messayke S, Michel M, Lambotte O, Michot JM.

Am J Hematol. | 2024 Jul;99(7):1427-1430. doi: 10.1002/ajh.27339. Epub 2024 Apr 20. PMID: 38642007No abstract available.

Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.

Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM.

Eur J Cancer. | 2024 Jul;205:114075. doi: 10.1016/j.ejca.2024.114075. Epub 2024 May 4. PMID:38733717Review.

Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.

Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, Michot JM, M Ribeiro J, Scotte F, Ponce Aix S, Lambotte O, Baldini C, Champiat S.

Cancer Treat Rev. | 2024 Jun;127:102751. doi: 10.1016/j.ctrv.2024.102751. Epub 2024 May 4.PMID:38729086Review.

Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?

Pourmir I, Nebbache R, Champiat S, Lambotte O; Cancer Immunotherapy Adverse Events Working Group.

Ann Oncol. | 2024 Jun;35(6):569-570. doi: 10.1016/j.annonc.2024.03.006. Epub 2024 Mar 26. PMID:38548063No abstract available.

Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.

Cariou PL, Pobel C, Michot JM, Danlos FX, Besse B, Carbonnel F, Mariette X, Marabelle A, Messayke S, Robert C, Routier E, Noël N, Lambotte O.

Eur J Cancer. | 2024 Jun;204:114065. doi: 10.1016/j.ejca.2024.114065. Epub 2024 Apr 14. PMID:38643707

Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.

Cancer Treat Rev.

Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, Michot JM, M Ribeiro J, Scotte F, Ponce Aix S, Lambotte O, Baldini C, Champiat S. | 2024 Jun;127:102751. doi: 10.1016/j.ctrv.2024.102751. Epub 2024 May 4. PMID: 38729086 Free article. Review.

Editorial: Another brick in the CDST wall.

Amiot A, Antoine M, Carbonnel F.

Aliment PharmacolTher. | 2024 May 17. doi: 10.1111/apt.18023. Online ahead of print. PMID: 38760922 No abstract available.

Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.

Singh N, Shahane A, Sparks JA, Bitoun S, Cappelli LC.

Rheum Dis Clin North Am. | 2024 May;50(2):269-279. doi: 10.1016/j.rdc.2024.02.002. Epub 2024 Mar 8. PMID: 38670725Review.

Immune Checkpoint Inhibitor-induced Sicca Syndrome.

Bitoun S, Rousseau A, Gosset M, Belkhir R, Lazure T, Mariette X, Nocturne G.

Rheum Dis Clin North Am. | 2024 May;50(2):291-300. doi: 10.1016/j.rdc.2024.02.004. PMID: 38670727Review.

Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.

Cariou PL, Pobel C, Michot JM, Danlos FX, Besse B, Carbonnel F, Mariette X, Marabelle A, Messayke S, Robert C, Routier E, Noël N, Lambotte O.

Eur J Cancer. | 2024 Apr 14;204:114065. doi: 10.1016/j.ejca.2024.114065. Online ahead of print. PMID: 38643707

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A.

J Immunother Cancer. | 2024 Apr 18;12(4):e008378. doi: 10.1136/jitc-2023-008378. PMID: 38641350Free PMC article.

Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.

Gougis P, Hamy AS, Jochum F, Bihan K, Carbonnel M, Salem JE, Dumas E, Kabirian R, Grandal B, Barraud S, Coussy F, Hotton J, Savarino R, Marabelle A, Cadranel J, Spano JP, Laas E, Reyal F, Abbar B.

JAMA Netw Open. | 2024 Apr 1;7(4):e245625. doi: 10.1001/jamanetworkopen.2024.5625. PMID: 38630478Free PMC article.

Drug-induced autoimmune hemolyticanemias related to immune checkpoint inhibitors, therapeutic management, and outcome.

Plaçais M, Laparra A, Maria ATJ, Kramkimel N, Perret A, Manson G, Comont T, Coutte L, Nardin C, Ouali K, Danlos FX, Noël N, Messayke S, Michel M, Lambotte O, Michot JM.

Am J Hematol. | 2024 Apr 20. doi: 10.1002/ajh.27339. Online ahead of print. PMID: 38642007

Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors.

Jeay M, Carbonnel F, Robert C, Mussini C, Bellanger C, Meyer A.

Clin Res Hepatol Gastroenterol. | 2024 Apr;48(4):102311. doi: 10.1016/j.clinre.2024.102311. Epub 2024 Feb 29.PMID: 38430989 Free article.

Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature.

Kachaner A, Seror R, Aubart FC, Henry J, Lazure T, Emile JF, Mariette X, Bitoun S.

JBMR Plus. | 2024 Apr 20;8(5):ziae043. doi: 10.1093/jbmrpl/ziae043. eCollection 2024 May. PMID: 38644976Free PMC article.

Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases.

Blanchard F, Henry B, Vijayaratnam S, Canouï E, Moura A, Thouvenot P, Bracq-Dieye H, Tessaud-Rita N, Valès G, Diakité A, Leclercq A, Lecuit M, Charlier C; Listeria monocytogenes-associated Spontaneous Peritonitis Study Group.

Lancet Infect Dis. | 2024 Apr 9:S1473-3099(24)00151-8. doi: 10.1016/S1473-3099(24)00151-8. Online ahead of print.PMID: 38608698

Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?

Pourmir I, Nebbache R, Champiat S, Lambotte O; Cancer Immunotherapy Adverse Events Working Group.

Ann Oncol. | 2024 Mar 26:S0923-7534(24)00083-8. doi: 10.1016/j.annonc.2024.03.006. Online ahead of print. PMID: 38548063 No abstract available.

Clonal CD8+ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma.

Krzysiek R, Bitoun S, Belkhir R, Hacein-Bey-Abina S, Mariette X.

Haematologica. | 2024 Mar 28. doi: 10.3324/haematol.2023.284942. Online ahead of print. PMID: 38546659

Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.

Faganello D, Bertrand A, Meunier P, Avouac J, Toussirot E, Coury F, Seror R, Le Mélédo G, Germain V, Dellal A, Shima D, Hulin C, Prati C, Schaeverbeke T, Richez C, Truchetet ME, Kostine M.

Rheumatology (Oxford). | 2024 Mar 1;63(3):787-790. doi: 10.1093/rheumatology/kead187.PMID: 37540112

High rate of progression to symptomatic multiple myeloma in patients with smoldering myeloma and isolated osteoporotic vertebral fracture.

Chevalier K, Hamroun S, Bitoun S, Henry J, Roux C, Briot K, Belkhir R, Mariette X, Seror R.

Bone Rep. | 2024 Mar 25;21:101755. doi: 10.1016/j.bonr.2024.101755. eCollection 2024 Jun.PMID: 38577249 Free PMC article.

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.

Nguyen Y, Nocturne G, Henry J, Ng WF, Belkhir R, Desmoulins F, Bergé E, Morel J, Perdriger A, Dernis E, Devauchelle-Pensec V, Sène D, Dieudé P, Couderc M, Fauchais AL, Larroche C, Vittecoq O, Salliot C, Hachulla E, Le Guern V, Gottenberg JE, Mariette X, Seror R.

Lancet Rheumatol. | 2024 Mar 1:S2665-9913(23)00340-5. doi: 10.1016/S2665-9913(23)00340-5. Online ahead of print. PMID: 38437852

Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID.

Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A, Buisson A, Bouguen G, Le Berre C, Reenaers C, Le Cosquer G, Savoye G, Charkaoui M, Vidon M, Guillo L, Fumery M, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y; GETAID TOFA-PRO study group.

J Crohns Colitis. | 2024 Mar 1;18(3):424-430. doi: 10.1093/ecco-jcc/jjad169.PMID: 37796025 Free article.

Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.

Meyer A, Dong C, Chan SSM, Touvier M, Julia C, Huybrechts I, Nicolas G, Oldenburg B, Heath AK, Tong TYN, Key TJ, Tjønneland A, Kyrø C, Kaaks R, Katzke VA, Bergman MM, Palli D, Masala G, Tumino R, Sacerdote C, Colorado-Yohar SM, Sánchez MJ, Guevara M, Grip O, Holmgren J, Cross A, Karling P, Hultdin J, Murphy N, Deschasaux-Tanguy M, Hercberg S, Galan P, Mahamat-Saleh Y, Amiot A, Gunter MJ, Boutron-Ruault MC, Carbonnel F.

Aliment PharmacolTher. | 2024 Feb;59(4):558-568. doi: 10.1111/apt.17835. Epub 2023 Dec 15.PMID: 38100159 Free PMC article.

Obinutuzumab in patients with Sjogren's disease immunised against rituximab.

Pezot M, Nocturne G, Belkhir R, Henry J, Pavy S, Seror R, Mariette X, Bitoun S.

Ann Rheum Dis. | 2024 Feb15;83(3):407-408. doi: 10.1136/ard-2023-224999.PMID: 37945315 No abstract available.

Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group.

Nguyen Y, Beydon M, Foulquier N, Gordon R, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, McCoy SS, Cornec D, Seror R.

Semin Arthritis Rheum. | 2024 Jan 30;65:152385. doi: 10.1016/j.semarthrit.2024.152385. Online ahead of print. PMID: 38340608

[Managing cancer immunotherapy toxicities: Challenges and rechallenges for (young) internists].

Guitton R, Lambotte O, Chiche L.

Rev Med Interne. | 2024 Jan;45(1):1-5. doi: 10.1016/j.revmed.2023.12.003. Epub 2023 Dec 29. PMID: 38158294

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease.

Meyer A, Miranda S, Drouin J, Weill A, Carbonnel F, Dray-Spira R.

Clin Gastroenterol Hepatol. | 2024 Jan 8:S1542-3565(24)00010-7. doi: 10.1016/j.cgh.2023.12.029. Online ahead of print.PMID: 38199301

Publications of 2023

Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers.

Bredel D, Tihic E, Mouraud S, Danlos FX, Susini S, Aglave M, Alfaro A, Mohamed-Djalim C, Rouanne M, Halse H, Bigorgne A, Tselikas L, Dalle S, Hartl DM, Baudin E, Guettier C, Vibert E, Rosmorduc O, Robert C, Ferlicot S, Parier B, Albiges L, de Montpreville VT, Besse B, Mercier O, Even C, Breuskin I, Classe M, Radulescu C, Lebret T, Pautier P, Gouy S, Scoazec JY, Zitvogel L, Marabelle A, Bonvalet M.

J Exp Clin Cancer Res. | 2023 Dec 6;42(1):333. doi: 10.1186/s13046-023-02897-6. PMID: 38057799 Free PMC article.

Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series.

Bresteau C, Bonnet P, Robert C, Mussini C, Saiag P, Buecher B, Lebbe C, Allez M, Benamouzig R, Hagège H, Bécheur H, Meyer A, Carbonnel F.

J GastroenterolHepatol. | 2023 Dec;38(12):2104-2110. doi: 10.1111/jgh.16349. Epub 2023 Sep 14.PMID: 37710354

The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5.

Bouhnik Y, Carbonnel F, Fumery M, Flamant M, Buisson A, Camoin A, Addison J.

Dig Liver Dis. | 2023 Dec;55(12):1658-1666. doi: 10.1016/j.dld.2023.05.025. Epub 2023 Jun 10.PMID: 37308394 Free article.

Epidemiology of Sjögren syndrome

Maxime Beydon, Sara McCoy, Yann Nguyen, Takayuki Sumida, Xavier Mariette & Raphaèle Seror

Nat Rev Rheumatol. | 2023 Dec 18. doi: 10.1038/s41584-023-01057-6. PMID: 38110617 Review.

Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy in TRACTISS trial of Sjogren's syndrome.

Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, Lucchesi D, Fossati-Jimack L, Nerviani A, Jaworska E, Ghirardi GM, Giacomassi C, Emery P, Ng WF, Sutcliffe N, Everett CC, Fernandez C, Tappuni AR, Seror R, Mariette X, Porcher R, Cavallaro G, Pulvirenti A, Verstappen G, de Wolff L, Arends S, Bootsma H, Lewis MJ, Pitzalis C, Bowman SJ, Bombardieri M; TRACTISS Study research group.

Arthritis Rheumatol. | 2023 Dec 10. doi: 10.1002/art.42772. Online ahead of print. PMID: 38073013

Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.

Alouani E, Laparra A, Perret A, Sakkal M, Messayke S, Danlos FX, Ouali K, Hollebecque A, Even C, Ammari S, Baldini C, Champiat S, Besse B, Robert C, Guettier C, Samuel D, Lambotte O, De Martin E, Michot JM.

Eur J Cancer. | 2023 Nov;193:113313. doi: 10.1016/j.ejca.2023.113313. Epub 2023 Aug 26. PMID: 37748398

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.

Ladouceur A, Barnetche T, Mouterde G, Tison A, Bitoun S, Prey S, Dutriaux C, Gerard E, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R, Domblides C, Daste A, Gross-Goupil M, Sionneau B, Lefort F, Larroquette M, Richez C, Truchetet ME, Schaeverbeke T, Kostine M.

RMD Open. | 2023 Nov 29;9(4):e003795. doi: 10.1136/rmdopen-2023-003795. PMID:38030233

Sjögren Syndrome: A Forgotten or an Overdiagnosed Entity?

Mariette X.

J Rheumatol. | 2023 Nov 1:jrheum.2023-0964. doi: 10.3899/jrheum.2023-0964. Online ahead of print. PMID: 37914214

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study.

Maxime Beydon, Sandrine Pinto, Yann De Rycke, Bruno Fautrel, Xavier Mariette, Raphaèle Seror, Florence Tubach et al.

The Lancet Regional Health – Europe. | Open Access Published: October 29, 2023DOI:https://doi.org/10.1016/j.lanepe.2023.100768

Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study.

Charles C, Bardet A, Ibrahimi N, Aromatario O, Cambon L, Imbert A, Pons M, Raynard B, Sauveplane D, Pouchepadass C, Baudinet C, Lambotte O, Marabelle A, Dauchy S.

J Telemed Telecare. | 2023 Oct;29(9):716-724. doi: 10.1177/1357633X211021743. Epub 2021 Jun 17.PMID: 34137641

Association Between Bruton's Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren's Syndrome.

Duret PM, Schleiss C, Kawka L, Meyer N, Ye T, Saraux A, Devauchelle-Pensec V, Seror R, Larroche C, Perdriger A, Sibilia J, Vallat L, Fornecker LM, Nocturne G, Mariette X, Gottenberg JE.

Arthritis Rheumatol. | 2023 Oct;75(10):1798-1811. doi: 10.1002/art.42550. Epub 2023 Jul 28.PMID: 37115807

Secondary hypertrophic osteoarthropathy revealing a metastatic melanoma.

Laillet J, Monnet P, Goldfarb L, Belkhir R, Robert C.

Eur J Cancer. | 2023 Oct;192:113247. doi: 10.1016/j.ejca.2023.113247. Epub 2023 Aug 23. PMID:37625239No abstract available.

Comparison between primary Sjögren's disease patients with high or low level of dryness.

Kachaner A, Bergé E, Desmoulins F, Le Pajolec C, Rousseau A, Labetoulle M, Nocturne G, Mariette X, Seror R.

RMD Open. | 2023 Oct;9(4):e003291. doi: 10.1136/rmdopen-2023-003291. PMID: 37899092 Free PMC article.

Ocular surface toxicities associated with modern anticancer therapies.

Boucher R, Haigh O, Barreau E, Champiat S, Lambotte O, Adam C, Labetoulle M, Rousseau A.

SurvOphthalmol. | 2023 Oct 6:S0039-6257(23)00134-0. doi: 10.1016/j.survophthal.2023.10.002. Online ahead of print. PMID: 37806566 Review.

Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.

Berry JS, Tarn J, Casement J, Duret PM, Scott L, Wood K, Johnsen SJ, Nordmark G, Devauchelle-Pensec V, Seror R, Fisher B, Barone F, Bowman SJ, Bombardieri M, Lendrem D, Felten R, Gottenberg JE, Ng WF.

Annals of the Rheumatic Diseases | 2023 Sep 1:ard-2023-224503. doi: 10.1136/ard-2023-224503. PMID: 37657927

Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Narula N, Chang NH, Mohammad D, Wong ECL, Ananthakrishnan AN, Chan SSM, Carbonnel F, Meyer A.

Clin Gastroenterol Hepatol. | 2023 Sep;21(10):2483-2495.e1. doi: 10.1016/j.cgh.2023.01.012. Epub 2023 Jan 31. PMID: 36731590 Review.

Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children.

Meyer A, Rios P, Drouin J, Weill A, Carbonnel F, Dray-Spira R.

Clin Gastroenterol Hepatol. | 2023 Sep;21(10):2679-2681.e5. doi: 10.1016/j.cgh.2022.08.028. Epub 2022 Sep 5. PMID: 36064096 No abstract available.

Efficacy of daratumumab in refractory primary Sjögren disease.

Nocturne G, Marmontel O, di Filippo M, Chretien P, Krzysiek R, Lifermann F, Rahal N, Belkhir R, Moulin P, Mariette X.

RMD Open. | 2023 Sep;9(3):e003464. doi: 10.1136/rmdopen-2023-003464. PMID: 37730313 Free PMC article. No abstract available.

WallFlex® and Evolution® Duodenal Stents Have Similar Efficacy but Different Safety for Malignant Gastric Outlet Obstruction.

Meyer A, Martin A, Bellanger C, Carbonnel F, Boytchev I.

Dig Dis Sci. | 2023 Sep;68(9):3688-3693. doi: 10.1007/s10620-023-08036-7. Epub 2023 Jul 21.PMID: 37477765

Liposomal AntagomiR-155-5p restores anti-inflammatory macrophages and improves arthritis in pre-clinical models of Rheumatoid arthritis.

Paoletti A, Ly B, Cailleau C, Gao F, Péan de Ponfilly-Sotier M, Pascaud J, Rivière E, Yang L, Nwosu L, Elmesmari A, Reynaud F, Hita M, Paterson D, Reboud J, Fay F, Nocturne G, Tsapis N, McInnes IB, Kurowska-Stolarska M, Fattal E, Mariette X

Arthritis Rheumatol | 2023 Aug 1. doi: 10.1002/art.42665. PMID: 37527031

Post-transcriptional checkpoints in autoimmunity

Bechara R, Vagner S, Mariette X.

Nature Reviews Rheumatology | 2023 Aug;19(8):486-502. doi: 10.1038/s41584-023-00980-y. Epub 2023 Jun 13. PMID: 37311941 Review.

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.

Bitoun S, Hässler S, Ternant D, Szely N, Gleizes A, Richez C, Soubrier M, Avouac J, Brocq O, Sellam J, de Vries N, Huizinga TWJ, Jury EC, Manson JJ, Mauri C, Matucci A, Hacein Bey Abina S, Mulleman D, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

JAMA Netw Open | 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098. PMID: 37436748

Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis.

Duquesne J, Bouget V, Cournède PH, Fautrel B, Guillemin F, de Jong PHP, Heutz JW, Verstappen M, van der Helm-van Mil AHM, Mariette X, Bitoun S.

Rheumatology (Oxford). | 2023 Jul 5;62(7):2402-2409. doi: 10.1093/rheumatology/keac645. PMID:36416134Free PMC article.

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.

Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, MbogningFonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L.

Science. | 2023 Jun 9;380(6649):eabo2296. doi: 10.1126/science.abo2296. Epub 2023 Jun 9. PMID: 37289890

Food Processing and Risk of Crohn's Disease and Ulcerative Colitis: A European Prospective Cohort Study.

Meyer A, Dong C, Casagrande C, Chan SSM, Huybrechts I, Nicolas G, Rauber F, Levy RB, Millett C, Oldenburg B, Weiderpass E, Heath AK, Tong TYN, Tjønneland A, Kyrø C, Kaaks R, Katzke VA, Bergman MM, Palli D, Masala G, Tumino R, Sacerdote C, Colorado-Yohar SM, Sánchez MJ, Grip O, Lindgren S, Luben R, Gunter MJ, Mahamat-Saleh Y, Boutron-Ruault MC, Carbonnel F.

Clin GastroenterolHepatol. | 2023Jun;21(6):1607-1616.e6. doi: 10.1016/j.cgh.2022.09.031. Epub 2022 Oct 12. PMID: 36243353

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.

Liu C, Shatila M, Mathew A, Machado AP, Thomas A, Zhang HC, Thomas AS, Faleck D, Funchain P, Philpott J, Grivas P, Obeid M, Carbonnel F, Wang Y.

J Cancer. | 2023 Jun 26;14(10):1913-1919. doi: 10.7150/jca.84261. eCollection 2023.PMID: 37476185 Free PMC article.

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.

Coustal C, Vanoverschelde J, Quantin X, Lesage C, Michot JM, Lappara A, Ederhy S, Assenat E, Faure M, Issa N, Lambotte O, Puyade M, Dereure O, Tosi D, Rullier P, Serre I, Larcher R, Klouche K, Chanques G, Vernhet-Kovacsik H, Faillie JL, Agullo A, Roubille F, Guilpain P, Maria ATJ.

J Immunother Cancer. | 2023 May;11(5):e004792. doi: 10.1136/jitc-2022-004792. PMID: 37258037

Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.

Meyer A, Amiot A, Carbonnel F.

Aliment PharmacolTher. | 2023 May;57(9):1032-1033. doi: 10.1111/apt.17432.PMID: 37053477 No abstract available.

[An overview of immune checkpoint inhibitors toxicities].

Rouvet G, Lambotte O.

Med Sci (Paris). | 2023 May;39(5):445-451. doi: 10.1051/medsci/2023066. Epub 2023 May 23. PMID: 37219349 French.

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.

Carbonnel F, Routier E, Lazure T, Mussini C, Bellanger C, Merklen C, Bejou B, Buisson A, Amiot A, Meyer A, Dong C, Robert C.

Aliment PharmacolTher. | 2023 Apr;57(7):792-799. doi: 10.1111/apt.17352. Epub 2022 Dec 28.PMID: 36578099

Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma.

Ascione S, Harel S, Besson FL, Belkhir R, Henry J, Royer B, Arnulf B, Mariette X, Seror R.

Haematologica | 2023 Mar 23. doi: 10.3324/haematol.2022.282214. Online ahead of print. PMID:36951162

Cancer screening in chronic inflammatory rheumatic diseases.

Joanna Kedra, Raphaèle Seror

Joint Bone Spine | 2023 Feb 24:105557. doi: 10.1016/j.jbspin.2023.105557. Online ahead of print.PMID: 36842758

Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis.

Yu Z, Tsapis N, Fay F, Chen L, Karpus A, Shi X, Cailleau C, García Pérez S, Huang N, Vergnaud J, Mignani S, Majoral JP, Fattal E.

Biomacromolecules | 2023 Feb 13;24(2):667-677. doi: 10.1021/acs.biomac.2c01117. Epub 2023 Jan 4.

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.

Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, Sühs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G; Immunotherapy for PML Study Group.

Ann Neurol. | 2023 Feb;93(2):257-270. doi: 10.1002/ana.26512. Epub 2022 Oct 17.PMID: 36151879 Free PMC article.

Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.

Antoun S, Lanoy E, Ammari S, Farhane S, Martin L, Robert C, Planchard D, Routier E, Voisin AL, Messayke S, Champiat S, Michot JM, Laghouati S, Lambotte O, Marabelle A, Baracos V.

Eur J Cancer. | 2023 Jan;178:49-59. doi: 10.1016/j.ejca.2022.10.013. Epub 2022 Oct 27.PMID: 36403367

Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.

Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, Teysseire S, Danlos FX, Albiges L, Bernigaud C, Benderra MA, Pradère P, Zaidan M, Decroisette C, Fallah F, Matergia G, Lavaud P, Jantzem H, Atzenhoffer M, Buyse V, Ammari S, Robert C, Champiat S, Messayke S, Marabelle A, Guettier C, Lebbe C, Lambotte O, Michot JM.

Eur J Cancer. | 2023 Jan;179:28-47. doi: 10.1016/j.ejca.2022.11.001. Epub 2022 Nov 12.PMID: 36473326

Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.

Guillo L, Flachaire B, Avouac J, Dong C, Nachury M, Bouguen G, Buisson A, Caillo L, Fumery M, Gilletta C, Hébuterne X, Lafforgue P, Laharie D, Mahé E, Marotte H, Nancey S, Ottaviani S, Salmon JH, Savoye G, Serrero M, Uzzan M, Viguier M, Richez C, Peyrin-Biroulet L, Seksik P, Pham T; COMBIO Study Group.

Dig Liver Dis. | 2023 Jan;55(1):61-68. doi: 10.1016/j.dld.2022.07.012. Epub 2022 Aug 16. PMID: 35985961

Editorial: ustekinumab during pregnancy - reassuring but still not enough.

Amiot A, Meyer A, Carbonnel F.

Aliment PharmacolTher. | 2023 Jan;57(1):158-159. doi: 10.1111/apt.17260.PMID: 36480723 No abstract available.

Publications of 2022

Using genetics to predict toxicity of cancer immunotherapy

Caroline Robert, Stéphan Vagner & Xavier Mariette

Nature Medicine | volume 28, pages2471–2472 (2022)

Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity

Loïc Meudec, Pauline Richebé, Juliette Pascaud, Xavier Mariette, Gaetane Nocturne

Rheumatology | keac710, https://doi.org/10.1093/rheumatology/keac710

Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies.

Hernández-Molina G, Kostov B, Brito-Zerón P, Vissink A, Mandl T, Hinrichs AC, Quartuccio L, Baldini C, Seror R, Szántó A, Isenberg D, Gerli R, Nordmark G, Rasmussen A, Solans-Laque R, Hofauer B, Sène D, Pasoto SG, Rischmueller M, Praprotnik S, Gheita TA, Danda D, Armağan B, Suzuki Y, Valim V, Devauchelle-Pensec V, Retamozo S, Kvarnstrom M, Sebastian A, Atzeni F, Giacomelli R, Carsons SE, Kwok SK, Nakamura H, Fernandes Moça Trevisani V, Flores-Chávez A, Mariette X, Ramos-Casals M; Sjögren Big Data Consortium.

Rheumatology (Oxford). | 2022 Dec 23;62(1):243-255. doi: 10.1093/rheumatology/keac205.PMID: 35385104

Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies.

Alouani E, Rousseau B, Andre T, Marabelle A.

Nat Cancer. | 2022 Dec;3(12):1414-1417. doi: 10.1038/s43018-022-00497-5. PMID: 36539500No abstract available.

Lifestyle factors for the prevention of inflammatory bowel disease.

Lopes EW, Chan SSM, Song M, Ludvigsson JF, Håkansson N, Lochhead P, Clark A, Burke KE, Ananthakrishnan AN, Cross AJ, Palli D, Bergmann MM, Richter JM, Chan AT, Olén O, Wolk A, Khalili H; EPIC-IBD investigators.

Gut. | 2022 Dec 6:gutjnl-2022-328174. doi: 10.1136/gutjnl-2022-328174. Online ahead of print.PMID: 36591609

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.

Ann Oncol. | 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18.PMID: 36270461 Free article. No abstract available.

Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes.

Japiassu KB, Fay F, Marengo A, Louaguenouni Y, Cailleau C, Denis S, Chapron D, Tsapis N, Nascimento TL, Lima EM, Fattal E.

J Control Release | 2022 Dec;352:15-24. doi: 10.1016/j.jconrel.2022.10.006. Epub 2022 Oct 14. PMID: 36209941

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.

Meyer A, Fumery M, Peyrin-Biroulet L, Filippi J, Altwegg R, Bouhnik Y, Serrero M, Laharie D, Roblin X, Nachury M, Abitbol V, Cadiot G, Nancey S, Allez M, Gilletta C, Vuitton L, Savoye G, Nahon S, Bourrier A, Buisson A, Bouguen G, Bourreille A, Viennot S, Carbonnel F, Amiot A.

Scand J Gastroenterol. | 2022 Dec;57(12):1454-1462. doi: 10.1080/00365521.2022.2095668. Epub 2022 Jul 12. PMID: 35819361

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, Texier M.

Cancer Treat Rev. | 2022 Nov;110:102452. doi: 10.1016/j.ctrv.2022.102452. Epub 2022 Aug 10.PMID: 35998515 Free article. Review.

Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).

Gottenberg JE, Chaudier A, Allenbach Y, Mekinian A, Amoura Z, Cacoub P, Cornec D, Hachulla E, Quartier P, Melki I, Richez C, Seror R, Terrier B, Devauchelle-Pensec V, Henry J, Gatfosse M, Bouillet L, Gaigneux E, Andre V, Baulier G, Saunier A, Desmurs M, Poulet A, Ete M, Bienvenu B, Truchetet ME, Michaud M, Larroche C, Dellal A, Leurs A, Ottaviani S, Nielly H, Vial G, Jaussaud R, Rouvière B, Jeandel PY, Guffroy A, Korganow AS, Jouvray M, Meyer A, Chatelus E, Sordet C, Felten R, Sibilia J, Litim-Ahmed-Yahia S, Kleinmann JF, Mariette X.

RMD Open. | 2022 Nov;8(2):e002324. doi: 10.1136/rmdopen-2022-002324.PMID: 36319066 Free PMC article.

CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia

Awatef Allouch, Laurent Voisin, Yanyan Zhang, Syed Qasim Raza, Yann Lecluse, Julien Calvo, Dorothée Selimoglu-Buet, Stéphane de Botton, Fawzia Louache, Françoise Pflumio, Eric Solary & Jean-Luc Perfettini.

Nature Communications | doi: 10.1038/s41467-022-34548-3 - Article number: 6739 (2022) - 08 November 2022

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report.

Aldea M, Belkhir R, Colomba E, Blanchard P, Danlos FX, Botticella A, Terlizzi M, Deutsch E, Le Péchoux C, Planchard D, Michot JM, Besse B, Levy A.

Front Immunol | 2022 Oct 24;13:920130. doi: 10.3389/fimmu.2022.920130. eCollection 2022. PMID: 36353627

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.

Peyraud F, Guégan JP, Bodet D, Nafia I, Fontan L, Auzanneau C, Cousin S, Roubaud G, Cabart M, Chomy F, Le Loarer F, Chaput N, Danlos FX, Planchard D, Even C, Khettab M, Tselikas L, Besse B, Barlesi F, Soria JC, Marabelle A, Bessede A, Italiano A.

Ann Oncol. | 2022 Oct;33(10):1041-1051. doi: 10.1016/j.annonc.2022.07.001. Epub 2022 Jul 16. PMID:35850444Clinical Trial.

Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.

Meyer A, Neumann A, Drouin J, Weill A, Carbonnel F, Dray-Spira R.

Ann Intern Med. | 2022 Oct;175(10):1374-1382. doi: 10.7326/M22-0819. Epub 2022 Sep 27.PMID: 36162111 Clinical Trial.

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study.

De La Fuente F, Belkhir R, Henry J, Nguyen CD, Pham T, Germain V, Gavand PE, Labadie C, Briere C, Lauret A, Cardon T, Mouterde G, Bonnet I, Rouxel L, Truchetet ME, Schaeverbeke T, Richez C, Kostine M; Club Rhumatismes and Inflammation (CRI).

RMD Open | 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612. PMID: 36270747

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.

Kedra J, Seror R, Dieudé P, Constantin A, Toussirot E, Kfoury E, Masson C, Cornec D, Dubost JJ, Marguerie L, Ottaviani S, Grados F, Belkhir R, Fain O, Fautrel B, Philippe P, Piperno M, Combe B, Lambotte O, Richez C, Sellam J, Sené T, Denis G, Lequerre T, Lazure T, Mariette X, Nocturne G.

Joint Bone Spine | 2022 Oct;89(5):105390. doi: 10.1016/j.jbspin.2022.105390. Epub 2022 Apr 28. PMID: 35490943

Immune-related adverse events of cancer immunotherapies targeting kinases.

Ramos-Casals M, Flores-Chávez A, Brito-Zerón P, Lambotte O, Mariette X.

Pharmacol Ther | 2022 Sep;237:108250. doi: 10.1016/j.pharmthera.2022.108250. Epub 2022 Jul 14. PMID: 35843306

Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.

Boschetti G, Nachury M, Laharie D, Roblin X, Gilletta C, Aubourg A, Bourreille A, Zallot C, Hebuterne X, Buisson A, Grimaud JC, Bouhnik Y, Allez M, Altwegg R, Viennot S, Vuitton L, Carbonnel F, Paul S, Desseaux K, Lambert J, Peyrin-Biroulet L.

Am J Gastroenterol. | 2022 Sep 1;117(9):1482-1490. doi: 10.14309/ajg.0000000000001842. Epub 2022 Jun 2. PMID: 35973142

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts.

Bouget V, Duquesne J, Hassler S, Cournède PH, Fautrel B, Guillemin F, Pallardy M, Broët P, Mariette X, Bitoun S.

RMD Open | 2022 Aug;8(2):e002442. doi: 10.1136/rmdopen-2022-002442. PMID: 35999028

Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID.

Reenaers C, de Roover A, Kohnen L, Nachury M, Simon M, Pourcher G, Trang-Poisson C, Rajca S, Msika S, Viennot S, Alttwegg R, Serrero M, Seksik P, Peyrin-Biroulet L, Picon L, BourbaoTournois C, Gontier R, Gilletta C, Stefanescu C, Laharie D, Roblin X, Nahon S, Bouguen G, Carbonnel F, Attar A, Louis E, Coffin B.

Inflamm Bowel Dis. | 2022 Aug 1;28(8):1198-1206. doi: 10.1093/ibd/izab249.PMID: 34636895

Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.

Maio M, Amonkar MM, Norquist JM, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH Jr, Oh DY, Gottfried M, Wang R, Norwood K, Marabelle A.

Eur J Cancer. | 2022 Jul;169:188-197. doi: 10.1016/j.ejca.2022.03.040. Epub 2022 May 16. PMID:35588692

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.

Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B, Mariette X, Tubach F.

RMD Open | 2022 Jun;8(2):e002139. doi: 10.1136/rmdopen-2021-002139. PMID: 35738803

Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.

Meyer A, Taine M, Drouin J, Weill A, Carbonnel F, Dray-Spira R.

Clin Gastroenterol Hepatol. | 2022 Jun;20(6):1269-1281.e9. doi: 10.1016/j.cgh.2021.07.028. Epub 2021 Jul 21. PMID: 34298191

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses.

Bitoun S, Avouac J, Henry J, Ghossan R, Al Tabaa O, Belkhir R, Nocturne G, Mariaggi AA, Rozenberg F, Vauloup-Fellous C, Mariette X, Seror R.

RMD Open | 2022 May;8(1):e002308. doi: 10.1136/rmdopen-2022-002308. PMID: 35589332

Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.

Bitoun S, Henry J, Desjardins D, Vauloup-Fellous C, Dib N, Belkhir R, Mouna L, Joly C, Bitu M, Ly B, Pascaud J, Seror R, Roque Afonso AM, Le Grand R, Mariette X.

Arthritis Rheumatol | 2022 Jun;74(6):927-933. doi: 10.1002/art.42058. Epub 2022 Mar 29. PMID: 34962357

Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients.

Parreau S, Nocturne G, Mariette X, Burroni B, Lazure T, Besson FL, Régent A, Mouthon L, Terrier B, Seror R, Le Guern V.

Rheumatology (Oxford) | 2022 Aug 30;61(9):3818-3823. doi: 10.1093/rheumatology/keab949. PMID: 34940802

Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.

González-Sánchez E, Muñoz-Callejas A, Gómez-Román J, San Antonio E, Marengo A, Tsapis N, Bohne-Japiassu K, González-Tajuelo R, Pereda S, García-Pérez J, Cavagna L, González-Gay MÁ, Vicente-Rabaneda EF, Meloni F, Fattal E, Castañeda S, Urzainqui A

Br J Pharmacol | 2022 Sep;179(18):4534-4548. doi: 10.1111/bph.15898. Epub 2022 Jul 13. PMID:35726496

Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles.

Simón-Vázquez R, Tsapis N, Lorscheider M, Rodríguez A, Calleja P, Mousnier L, de Miguel Villegas E, González-Fernández Á, Fattal E.

Drug DelivTransl Res | 2022 May;12(5):1270-1284. doi: 10.1007/s13346-021-01112-3. Epub 2022 Jan 6. PMID:34993924Free PMC article

Obesity is Associated With Increased Risk of Crohn's disease, but not Ulcerative Colitis: A Pooled Analysis of Five Prospective Cohort Studies.

Chan SSM, Chen Y, Casey K, Olen O, Ludvigsson JF, Carbonnel F, Oldenburg B, Gunter MJ, Tjønneland A, Grip O; DEFINe-IBD Investigators; Lochhead P, Chan AT, Wolk A, Khalili H.

Clin Gastroenterol Hepatol. | 2022 May;20(5):1048-1058. doi: 10.1016/j.cgh.2021.06.049. Epub 2021 Jul

Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.

Camard M, Besse B, Cariou PL, Massayke S, Laparra A, Noel N, Michot JM, Ammari S, Pavec JL, Lambotte O.

Respir Med Res. | 2022 Nov;82:100969. doi: 10.1016/j.resmer.2022.100969. Epub 2022 Nov 9.PMID: 36370683

Ocular Inflammation Induced by Immune Checkpoint Inhibitors.

Chaudot F, Sève P, Rousseau A, Maria ATJ, Fournie P, Lozach P, Keraen J, Servant M, Muller R, Gramont B, Touhami S, Mahmoud H, Quintart PA, Dalle S, Lambotte O, Kodjikian L, Jamilloux Y.

J Clin Med. | 2022 Aug 25;11(17):4993. doi: 10.3390/jcm11174993.PMID: 36078923 Free PMC article.

Meat Intake Is Associated with a Higher Risk of Ulcerative Colitis in a Large European Prospective Cohort Studyø.

Dong C, Chan SSM, Jantchou P, Racine A, Oldenburg B, Weiderpass E, Heath AK, Tong TYN, Tjønneland A, Kyrø C, Bueno de Mesquita B, Kaaks R, Katzke VA, Bergman MM, Boeing H, Palli D, Masala G, Tumino R, Sacerdote C, Colorado-Yohar SM, Sánchez MJ, Grip O, Lindgren S, Luben R, Huybrechts I, Gunter MJ, Mahamat-Saleh Y, Boutron-Ruault MC, Carbonnel F.

J Crohns Colitis. | 2022 Aug 30;16(8):1187-1196. doi: 10.1093/ecco-jcc/jjac054.PMID: 35396592

[Toxicity of cancer immunotherapies: Traps to not miss, the role of the internist].

Lambotte O.

Rev Med Interne. | 2022 Aug;43(8):459-461. doi: 10.1016/j.revmed.2022.07.002. Epub 2022 Jul 22.PMID: 35879133 French. No abstract available.

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.

Melin A, Routier É, Roy S, Pradere P, Le Pavec J, Pierre T, Chanson N, Scoazec JY, Lambotte O, Robert C.

2022 Jun 14;14(12):2937. doi: 10.3390/cancers14122937.PMID: 35740604 Free PMC article. | Cancers (Basel).

Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy.

Martin de Fremont G, Belkhir R, Henry J, Voisin AL, Lambotte O, Besson FL, Mariette X, Nocturne G.

Ann Rheum Dis. | 2022 Mar;81(3):e52. doi: 10.1136/annrheumdis-2020-217225. Epub 2020 Mar 18.PMID: 32188691 No abstract available.

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group.

Lancet Gastroenterol Hepatol. | 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.PMID: 34798038 Free article. Clinical Trial.

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.

Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group.

Lancet Gastroenterol Hepatol. | 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.PMID: 34798039 Free article. Clinical Trial.

Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.

Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F, Meyer A.

Inflamm Bowel Dis. | 2022 Feb 1;28(2):218-225. doi: 10.1093/ibd/izab060.PMID: 33847351

Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.

Parrot L, Dong C, Carbonnel F, Meyer A.

Aliment PharmacolTher. | 2022 Feb;55(4):380-388. doi: 10.1111/apt.16714. Epub 2021 Dec 1. PMID: 34854100

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.

Flores-Chávez A, Brito-Zerón P, Retamozo S, Bitoun S, Fisher BA, Liew D, Suijkerbuijk K, Chatzidionysiou K, Suárez-Almazor M, Lambotte O, Mariette X, Ramos-Casals M.

Crit Rev Immunol. | 2022;42(4):21-36. doi: 10.1615/CritRevImmunol.2023047272.PMID: 37022357 Review.

Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.

Nguyễn T, Maria ATJ, Ladhari C, Palassin P, Quantin X, Lesage C, Taïeb G, Ayrignac X, Rullier P, Hillaire-Buys D, Lambotte O, Guilpain P, Faillie JL.

Ann Rheum Dis. | 2022 Feb;81(2):e32. doi: 10.1136/annrheumdis-2020-217018. Epub 2020 Feb 17.PMID: 32066555 Free article. No abstract available.

Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.

Panhaleux M, Espitia O, Terrier B, Manson G, Maria A, Humbert S, Godbert B, Perrin J, Achille A, Arrondeau J, Kostine M, Fallet V, Pugnet G, Chaigne B, Champiat S, Laparra A, Danlos FX, Launay D, Penel N, Lambotte O, Michot JM, Forestier A.

Eur J Cancer. | 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19.PMID: 34810048 Clinical Trial.

Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.

Carbonnel F, Meyer A.

Aliment PharmacolTher. | 2022 Jan;55(2):251-252. doi: 10.1111/apt.16709. PMID: 34970769 No abstract available.

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF.

Cachen L, Nocturne G, Collins M, Meyer A, Gleizes A, Hacein-Bey-Abina S, Carbonnel F, Mariette X, Seror R.

RMD Open. | 2022 Jan;8(1):e001697. doi: 10.1136/rmdopen-2021-001697.PMID: 35091460 Free PMC article.

Publications of 2021

Recommendations for risk management and better living with epilepsy. Phenomenological study of the experience of patients, relatives, and bereaved families.

OudeEngberink A, Faucanié M, Boulais M, Nègre-Pages L, Bourrel G, Jaussent A, Crespel A, Carbonnel F, Picot MC.

Epilepsy Behav. | 2021 Dec;125:108412. doi: 10.1016/j.yebeh.2021.108412. Epub 2021 Nov 14.PMID: 34788730

[Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].

Lecoq AL, Dong C, Carbonnel F, Becquemont L.

Therapie. | 2021 Nov-Dec;76(6):705-714. doi: 10.1016/j.therap.2021.04.008. Epub 2021 Apr 21.PMID: 33962799 Review. French.

Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis.

D'Arcy ME, Beachler DC, Pfeiffer RM, Curtis JR, Mariette X, Seror R, Mahale P, Rivera DR, Yanik EL, Engels EA.

Cancer Epidemiol Biomarkers Prev. | 2021 Nov;30(11):2059-2067. doi: 10.1158/1055-9965.EPI-21-0125. Epub 2021 Aug 23.PMID: 34426413 Free PMC article.

Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group.

Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, Gallois C, Touchefeu Y, Maillet M, Trouilloud I, Rompteaux P, Carbonnel F, Soularue E.

Clin Res Hepatol Gastroenterol. | 2021 Nov;45(6):101607. doi: 10.1016/j.clinre.2020.101607. Epub 2021 Mar 2. PMID: 33662776

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.

Bitoun S, Henry J, Vauloup-Fellous C, Dib N, Belkhir R, Mouna L, Joly C, Desjardins D, Bitu M, Le Grand R, Seror R, Roque Afonso AM, Mariette X.

J Hematol Oncol. | 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2. PMID: 34645504

Lymphoma complicating rheumatoid arthritis: results from a French case-control study.

Kedra J, Seror R, Dieudé P, Constantin A, Toussirot E, Kfoury E, Masson C, Cornec D, Dubost JJ, Marguerie L, Ottaviani S, Grados F, Belkhir R, Fain O, Goupille P, Sordet C, Fautrel B, Philippe P, Piperno M, Combe B, Lambotte O, Richez C, Sellam J, Sené T, Denis G, Lequerre T, Lazure T, Mariette X, Nocturne G.

RMD Open. | 2021 Sep;7(3):e001698. doi: 10.1136/rmdopen-2021-001698. PMID: 34470830

Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique.

Carretero C, Carbonnel F, Ferrante M, Knudsen T, Van Lent N, Lobo AJ, Negreanu L, Vojvodic A, Oliva S.

Curr Med Res Opin. | 2021 Sep;37(9):1547-1554. doi: 10.1080/03007995.2021.1940910. Epub 2021 Jun 30. PMID: 34132150

Chronic pouchitis and Crohn's disease of the pouch after ileal pouch-anal anastomosis: Incidence and risk factors.

Bresteau C, Amiot A, Kirchgesner J, de'Angelis N, Lefevre JH, Bouhnik Y, Panis Y, Beaugerie L, Allez M, Brouquet A, Carbonnel F, Meyer A.

Dig Liver Dis. | 2021 Sep;53(9):1128-1135. doi: 10.1016/j.dld.2021.03.027. Epub 2021 Apr 27.PMID: 33931341

Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice.

Nocturne G, Ly B, Paoletti A, Pascaud J, Seror R, Nicco C, Mackay F, Vincent FB, Lazure T, Ferlicot S, Stimmer L, Pascal Q, Roulland S, Krzysiek R, Hacein-Bey S, Batteux F, Mariette X.

Clin Exp Immunol. | 2021 Aug;205(2):169-181. doi: 10.1111/cei.13602. Epub 2021 May 30. PMID: 33864242

Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease.

Chevalier G, Laveissière A, Desachy G, Barnich N, Sivignon A, Maresca M, Nicoletti C, Di Pasquale E, Martinez-Medina M, Simpson KW, Yajnik V, Sokol H; MOBIDIC Study Investigators; Plassais J, Strozzi F, Cervino A, Morra R, Bonny C.

Microbiome. | 2021 Aug 23;9(1):176. doi: 10.1186/s40168-021-01135-5.PMID: 34425887 Free PMC article.

Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.

Uzzan M, Bresteau C, Laharie D, Stefanescu C, Bellanger C, Carbonnel F, Serrero M, Viennot S, Nachury M, Amiot A, Altwegg R, Picon L, Nahon S, Vuitton L, Ah Soune P, Kirchgesner J, Peyrin-Biroulet L, Bouhnik Y; GETAID-TALC Study Group.

Aliment PharmacolTher. | 2021 Aug;54(3):312-319. doi: 10.1111/apt.16463. Epub 2021 Jun 20.PMID: 34151448

Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.

Meyer A, Drouin J, Weill A, Carbonnel F, Dray-Spira R.

Aliment PharmacolTher. | 2021 Aug;54(3):302-311. doi: 10.1111/apt.16448. Epub 2021 Jun 23.PMID: 34162011

Inflammation-targeted therapies and cancer.

Kedra J, Nocturne G, Mariette X, Seror R.

Joint Bone Spine. | 2021 Jul;88(4):105176. doi: 10.1016/j.jbspin.2021.105176. Epub 2021 Mar 23. PMID: 33771759

Current and future therapies for primary Sjögren syndrome.

Seror R, Nocturne G, Mariette X.

Nat Rev Rheumatol. | 2021 Aug;17(8):475-486. doi: 10.1038/s41584-021-00634-x. Epub 2021 Jun 29.PMID: 34188206 Review.

Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

Morel J, Tournadre A, Sellam J, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Dieudé P, Goupille P, Kluger N, Lazaro E, Le Goff B, de Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Pham T, Richez C.

Joint Bone Spine. | 2021 Jun;88(4 Suppl 1):105221. doi: 10.1016/j.jbspin.2021.105221.PMID: 34183155 No abstract available.

Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.

Meyer A, Semenzato L, Zureik M, Weill A, Carbonnel F, Dray-Spira R.

Aliment PharmacolTher. | 2021 Jul;54(2):160-166. doi: 10.1111/apt.16410. Epub 2021 Jun 10. PMID: 34110040

Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

Tournadre A, Sellam J, Morel J, Jullien D, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Goupille P, Kluger N, Lazaro E, Goff BL, Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Richez C, Pham T.

Joint Bone Spine. | 2021 May;88(3 Suppl 1):105210. doi: 10.1016/j.jbspin.2021.105210.PMID: 34074455 No abstract available.

PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

Sellam J, Morel J, Tournadre A, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Dieudé P, Goupille P, Jullien D, Kluger N, Lazaro E, Le Goff B, de Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Pham T, Richez C.

Joint Bone Spine. | 2021 May;88(2 Suppl 1):105174. doi: 10.1016/j.jbspin.2021.105174.PMID: 33992225 No abstract available.

Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon.

Collins M, Michot JM, Bellanger C, Mussini C, Benhadji K, Massard C, Carbonnel F.

EXCLI J. | 2021 Apr26;20:819-827. doi: 10.17179/excli2021-3572. eCollection 2021.PMID: 34121974 Free PMC article.

Impact of an Education Programme on IBD Patients' Skills: Results of a Randomised Controlled Multicentre Study [ECIPE].

Moreau J, Hammoudi N, Marthey L, Trang-Poisson C, Nachury M, Altwegg R, Grimaud JC, Orempuller S, Hébuterne X, Aubourg A, Baudry C, Seksik P, Roblin X, Nahon S, Savoye G, Mesnard B, Stefanescu C, Simon M, Coffin B, Fumery M, Carbonnel F, Peyrin-Biroulet L, Desseaux K, Allez M; GETAID.

J Crohns Colitis. | 2021 Mar 5;15(3):432-440. doi: 10.1093/ecco-jcc/jjaa195.PMID: 32969469 Clinical Trial.

Oncogenetic landscape of lymphomagenesis in coeliac disease.

Cording S, Lhermitte L, Malamut G, Berrabah S, Trinquand A, Guegan N, Villarese P, Kaltenbach S, Meresse B, Khater S, Dussiot M, Bras M, Cheminant M, Tesson B, Bole-Feysot C, Bruneau J, Molina TJ, Sibon D, Macintyre E, Hermine O, Cellier C, Asnafi V, Cerf-Bensussan N; CELAC network.

Gut. | 2022 Mar;71(3):497-508. doi: 10.1136/gutjnl-2020-322935. Epub 2021 Feb 12.PMID: 33579790 Free PMC article.

Main publications from the project leaders pertaining to the FHU CARE

Primary Sjögren's Syndrome.

Mariette X, Criswell LA.

N Engl J Med | 2018 Mar 8;378(10):931-939.

B cells in the pathogenesis of primary Sjögren syndrome.

Nocturne G, Mariette X.

Nat Rev Rheumatol | 2018 Mar;14(3):133-145.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O.

JAMA Oncol | 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science | 2015 Nov 27;350(6264):1079-84.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G,* Zitvogel L.* (*Co-corresponding authors).

Science | 2018 Jan 5;359(6371):91-97.

Previous Publications related to the research project (not necessarily by members of the FHU CARE)

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol | 2017 Jun 1;28(6):1368-1379

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R.

JAMA | 2017 Nov 7;318(17):1679-1686.

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.

Ann Rheum Dis | 2017 Oct;76(10):1747-1750.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A.

Ann Oncol | 2016 Apr;27(4):559-74.

Association of the autoimmune disease scleroderma with an immunologic response to cancer

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A.

Science | 2014 Jan 10;343(6167):152-7.